Loading
A phase 1/2 trial of therascreen companion diagnostic kits, Fludarabine, Cyclophosphamide in head and neck squamous cell carcinoma, run by Beijing Biotech, now recruiting.
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC is a phase 1/2 interventional study registered as NCT07617805 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide. Conditions listed: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Cyclophosphamide, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Fludarabine, Cyclophosphamide, Cytotoxic chemotherapy.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, Cytotoxic chemotherapy.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/